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RESEARCH ARTICLE
Host-Microbe Biology

Juvenal Lopez,a Pek Man Ly,a Mario F. Feldmana
a

Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA

ABSTRACT The type VI secretion system (T6SS) is a critical weapon in bacterial war-

fare between Gram-negative bacteria. Although invaluable for niche establishment,
this machine represents an energetic burden to its host bacterium. Acinetobacter
baumannii is an opportunistic pathogen that poses a serious threat to public health
due to its high rates of multidrug resistance. In some A. baumannii strains, the T6SS
is transcriptionally downregulated by large multidrug resistance plasmids. Other
strains, such as the clinical isolate AbCAN2, express T6SS-related genes but lack T6SS
activity under laboratory conditions, despite not harboring these plasmids. This suggests that alternative mechanisms exist to repress the T6SS. Here, we used a transposon mutagenesis approach in AbCAN2 to identify novel T6SS repressors. Our
screen revealed that the T6SS of this strain is inhibited by a homolog of VgrG, an essential structural component of all T6SSs reported to date. We named this protein
inhibitory VgrG (VgrGi). Biochemical and in silico analyses demonstrated that the unprecedented inhibitory capability of VgrGi is due to a single amino acid mutation in
a widely conserved C-terminal domain of unknown function, DUF2345. We also
show that unlike in other bacteria, the C terminus of VgrG is essential for functional
T6SS assembly in A. baumannii. Our study provides insight into the architectural requirements underlying functional assembly of the T6SS of A. baumannii. We propose
that T6SS-inactivating point mutations are beneﬁcial to the host bacterium, since
they eliminate the energy cost associated with maintaining a functional T6SS, which
appears to be unnecessary for A. baumannii virulence.
IMPORTANCE Despite the clinical relevance of A. baumannii, little is known about

its fundamental biology. Here, we show that a single amino acid mutation in VgrG, a
critical T6SS structural protein, abrogates T6SS function. Given that this mutation
was found in a clinical isolate, we propose that the T6SS of A. baumannii is probably
not involved in virulence; this idea is supported by multiple genomic analyses showing that the majority of clinical A. baumannii strains lack proteins essential to the
T6SS. We also show that, unlike in other species, the C terminus of VgrG is a unique
architectural requirement for functional T6SS assembly in A. baumannii, suggesting
that over evolutionary time, bacteria have developed changes to their T6SS architecture, leading to specialized systems.
KEYWORDS T6SS, T6SS assembly, VgrG, bacterial competition, contractile injection
system, secretion systems, type VI secretion system

B

acterial life involves constant interactions between diverse bacterial species. These
bacterium-bacterium interactions underlie the formation of complex bacterial
communities, which are the subject of constant compositional changes due to factors,
such as nutrient availability and interbacterial antagonism (1, 2). Several seminal studies
have shown that it is essential for bacterial pathogens to outcompete the normal host
microbiota to establish a niche and cause disease (3–5). Interbacterial competition has
also been shown to facilitate the exchange of genetic material, thus promoting the
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dissemination of antibiotic resistance genes and virulence factors (6–9). Understanding
how bacteria compete with one another provides insight into a critical aspect of
bacterial life.
The type VI secretion system (T6SS) mediates interbacterial competition between
Gram-negative bacteria (2, 10, 11). It is composed of a minimum of thirteen conserved
structural proteins (TssA to TssM), most of which are encoded in a single locus (12).
These constituents assemble into a trans-envelope, bacteriophage tail-like structure
that delivers toxic effector proteins into adjacent bacterial cells (13, 14). The “tail” is a
cytosolic complex composed of a tube of Hcp (or TssD) hexamers topped with a spike
of three VgrG (or TssI) proteins and, in some cases, a single PAAR protein. Hcp, VgrG,
and PAAR bind antibacterial T6SS effectors, which target essential cell structures, such
as the cell wall, genetic material, or the cell membrane (15, 16). The spiked tube is in
turn encompassed by a contractile sheath comprised of TssB and TssC. When the
sheath contracts, it propels the effector-loaded spiked tube outward from the attacking
cell and into adjacent cells. After its contraction, the sheath is disassembled by the
ATPase ClpV (or TssH) to enable sheath constituents to be reused in subsequent T6SS
assemblies (17).
The dynamic T6SS tail is built from a multimeric protein complex known as the
baseplate, and it is anchored to the bacterial envelope by a membrane complex (18,
19). The membrane complex is composed of three membrane-associated proteins: TssJ,
TssM, and TssL (19). In contrast, the baseplate forms in the cytoplasm, beginning with
the trimerization of VgrG and the subsequent assembly of wedge proteins (TssE-G
and TssK) around the VgrG hub (20–22). Following its assembly, the baseplate interacts
with the membrane complex (18, 22, 23), and the tube and sheath assemble at the N
terminus of VgrG in a highly coordinated process facilitated by TssA (18, 24).
The T6SS is energetically costly (25). Thus, many T6SS-encoding bacteria tightly
regulate their T6SS at transcriptional, posttranscriptional, and/or posttranslational levels (26, 27). The complex regulatory networks governing T6SS activity enable bacteria
to respond according to environmental signals, including: temperature, pH, cation/
nutrient availability, osmolarity, and membrane perturbation (26, 28–36). For instance,
the antibacterial T6SS of Pseudomonas aeruginosa (HSI-I), regarded as a defensive T6SS,
remains silenced unless P. aeruginosa perceives an attack from a competing bacterium
(37). When an attack is perceived, a posttranslational threonine phosphorylation pathway activates the forkhead-associated domain-containing protein Fha1, ultimately
resulting in the assembly of a functional T6SS in the location of the perceived attack
(37). Thus, P. aeruginosa overcomes the high energy cost of the T6SS by preventing
futile T6SS attacks in the absence of competing bacteria. However, the mechanisms
underlying T6SS regulation in other less-studied medically relevant bacteria remain
poorly understood.
Acinetobacter baumannii is a Gram-negative bacterial pathogen with alarming rates
of multidrug resistance and mortality (38). We have previously shown that A. baumannii
strains encode a single, highly conserved T6SS locus (39). Despite the notable genetic
conservation, diverse A. baumannii strains possess varying levels of Hcp secretion, the
hallmark of T6SS activity. One subset of strains secretes Hcp under standard laboratory
conditions, indicating that they possess a constitutively active (or offensive) T6SS. A
second subset of strains possess a silenced T6SS because they harbor a family of
multidrug-resistance plasmids named large conjugative plasmids (LCPs), which transcriptionally repress the T6SS locus (40–42). The ﬁnal subset of A. baumannii strains
expresses T6SS-related genes and does not harbor an LCP but does not secrete Hcp
under standard laboratory conditions (39, 43–45). These strains are expected to regulate their T6SS by as-yet-uncharacterized mechanisms. The clinical A. baumannii strain
CAN2 (AbCAN2, formerly named Ab1225) expresses Hcp but does not secrete it under
standard laboratory conditions (39). Here, we report the whole-genome sequence of
AbCAN2 and determine that it encodes all genes necessary for a functional T6SS and
lacks an LCP. Using a transposon mutagenesis approach, we identiﬁed a VgrG homolog
as an unexpected inhibitor of the T6SS of AbCAN2. Our bioinformatics and biochemical
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FIG 1 AbCAN2 encodes conserved T6SS-related genes. A schematic of the T6SS locus and vgrG gene clusters
encoded by AbCAN2 is shown. Locus tags, as well as functional domains identiﬁed in tse1 and tse2, are indicated.

analyses provide insight into the characteristics that differentiate an inhibitory VgrG
from a canonical VgrG. Furthermore, we demonstrate a previously unappreciated role
for the C terminus of VgrG proteins in T6SS assembly in A. baumannii.
RESULTS
Clinical strain AbCAN2 encodes a T6SS locus. AbCAN2 is a coccygeal isolate
collected at the University of Alberta Hospital, Canada, with an inactive T6SS under
standard laboratory conditions (39). To gain a better understanding of why the T6SS is
inactive in this strain, we determined the whole-genome sequence of AbCAN2 (GenBank
accession number CP045428). We found that this strain does not harbor an LCP. In
addition, it encodes all genes required for a functional T6SS. In fact, the T6SS locus of
AbCAN2 is syntenic with that of other A. baumannii strains, including the lab strain A.
baumannii ATCC 17978 (Ab17978) (Fig. 1) (39). The T6SS genes of AbCAN2 and
Ab17978 present remarkably high levels of sequence conservation, ranging from 98 to
100% nucleotide identity (see Table S1 in the supplemental material). Besides encoding
12 of the 13 structural T6SS proteins conserved among Proteobacteria (Acinetobacter
species lack a TssJ homolog [39]), the T6SS locus of AbCAN2 also contains genes coding
for accessory proteins TagF, TagN, PAAR, and TagX. In addition, the T6SS locus harbors
genes that code for three hypothetical proteins that are conserved among Acinetobacter species, some of which have been shown to be essential for T6SS function (46, 47).
The speciﬁc roles of these proteins are yet to be elucidated.
AbCAN2 also encodes two vgrG gene clusters located remotely from its T6SS locus
(Fig. 1). We arbitrarily named the VgrGs of each cluster VgrG1 and VgrG2. Each VgrG is
encoded upstream of an open reading frame (ORF) containing a predicted rearrangement hotspot A (RhsA) domain. T6SS effectors of the RhsA family have been previously
reported to possess DNase activity (48–50); thus, it is possible that the proteins coded
by these ORFs possess nuclease activity. Given their genetic proximity to vgrG1 and
vgrG2, we expect these proteins to be T6SS effectors. Thus, we named these ORFs type
6 effector 1 (tse1) and tse2, respectively. Downstream of each tse1 and tse2 is an ORF
that we predict to be the cognate immunity proteins of these effectors. Immunity
proteins are commonly encoded downstream of their cognate effector, and they
inactive their cognate effector by speciﬁcally binding it and obstructing its active site
(10). Thus, we named these ORFs type six immunity 1 (tsi1) and tsi2, respectively.
A VgrG homolog inhibits the T6SS of AbCAN2. Our ﬁnding that AbCAN2 lacks
T6SS activity despite encoding all genes required for T6SS assembly and not harboring
an LCP led us to hypothesize that AbCAN2 encodes a novel T6SS repressor. To identify
the putative novel repressor of the T6SS, we generated a transposon mutant library and
screened mutants for Hcp secretion, using our high-throughput Hcp colony blot assay
(see Materials and Methods) (51). We hypothesized that genetic disruption of a T6SS
inhibitor would result in appreciable T6SS activity in a mutant strain. Of the ⬃3,000
colonies screened, we detected Hcp in culture supernatants of four unique mutant
strains, indicating that these transposon mutants possess an active T6SS (Fig. 2a).
January/February 2020 Volume 11 Issue 1 e02761-19
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FIG 2 VgrGi inhibits the T6SS of AbCAN2. (a) Western blot of OD-normalized whole-cell (WC) and supernatant (Sup) fractions
of wild-type (WT) or unique transposon insertion mutants of AbCAN2 probing for Hcp expression and secretion. (b) Schematic
of transposon insertion sites within vgrGi. G32, A853; G9, A1108; G31, A1362; F1A, A1846. (c) Western blot probing for Hcp
expression and secretion in AbCAN2 WT, ⌬vgrGi, or the complemented strain (vgrGi⫹). For panels a and c, RNAP was included
as a lysis and loading control. (d) Cumulative data (means ⫾ the standard deviations) of three independent T6SS killing assays,
each with technical duplicates. Surviving E. coli MG1655R pBAV-gfp were enumerated after a 3.5-h incubation with the
indicated AbCAN2 predator strains at a 10:1 predator/prey ratio. **, P ⫽ 0.001 (determined by one-way analysis of variance
[ANOVA], followed by Dunnett’s multiple-comparison test). For panels c and d, WT and ⌬vgrGi strains harboring empty vector
pWH1266 are shown. The Western blots shown are representative of three independent experiments.

Surprisingly, the gene disrupted in all four mutant strains was vgrG1 (Fig. 2b). VgrG is
a conserved structural component of all T6SSs reported to date. It is a modular protein
containing N-terminal domains structurally similar to spike complex proteins of bacteriophage contractile tails (gp27 and gp5), as well as C-terminal DUF2345 and transthyretin (TT)-like domains, whose roles are yet to be fully understood (20, 21, 52–54). VgrGs
are widely regarded as essential to T6SS assembly and function, being implicated in
roles such as baseplate formation, proper Hcp tube assembly, and effector delivery (18,
22, 24, 55). Thus, our result that a VgrG homolog inhibits the T6SS is against the current
paradigm of VgrG function. To conﬁrm our results, we generated a clean deletion
mutant of vgrG1 (hereafter referred to as vgrGi for inhibitory VgrG) and compared its
T6SS activity to that of wild-type (WT) AbCAN2, using Hcp secretion and bacterial killing
assays. Consistent with our previous result, Hcp was detected in the supernatant
fraction of ⌬vgrGi but not WT AbCAN2 or the complemented strain (vgrGi⫹), indicating
that VgrGi inhibits the T6SS of AbCAN2 (Fig. 2c and Fig. S1a). Similarly, AbCAN2⌬vgrGi,
but not WT or vgrGi⫹, demonstrated signiﬁcant levels of interbacterial killing when
coincubated with E. coli (Fig. 2d). Altogether, our data indicate that VgrGi inhibits T6SS
activity in AbCAN2.
VgrGi acts independently to inhibit the T6SS. A previous report in Vibrio cholerae
suggests that T6SS effectors may play a critical role in T6SS assembly (56). Thus, we
tested whether AbCAN2 effectors Tse1 and Tse2 or VgrG2 were involved in T6SS
inhibition. To this end, we generated mutant strains of AbCAN2 lacking tse/tsi1, tse/tsi2,
vgrG2, or both vgrGi and vgrG2 (⌬vgrGi,2) and determined their T6SS activity by Hcp
secretion assay. We did not detect Hcp in the supernatant fraction of any of the mutant
strains, indicating that VgrGi-mediated T6SS inhibition is independent of any proteins
encoded within the two vgrG clusters of AbCAN2 (Fig. 3). Importantly, we also found
that unlike ⌬vgrGi, ⌬vgrG2, and ⌬vgrGi,2 lack the ability to secrete Hcp and kill E. coli
(Fig. 3 and Fig. S1b). Together, these results demonstrate that VgrG2 acts as a canonical
January/February 2020 Volume 11 Issue 1 e02761-19
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FIG 3 Additional VgrG-related proteins are not involved in T6SS inhibition. Western blot of ODnormalized whole-cell (WC) and supernatant (Sup) fractions of wild-type (WT) AbCAN2 or the indicated
mutants probing for Hcp expression and secretion. RNAP is included as a lysis and loading control. The
Western blot shown is representative of three independent experiments.

VgrG; it is required for proper T6SS function and effector delivery into bacterial
competitors.
Next, we tested whether VgrGi-mediated T6SS inhibition is due to an intrinsic
property of AbCAN2 or whether VgrGi can also inhibit the T6SS of a heterologous host.
To this end, we expressed plasmid-borne 6⫻His-tagged VgrGi in Ab17978 lacking LCP
pAB3 (hereafter referred to as WT Ab17978), which possesses constitutive T6SS activity
under standard laboratory conditions (40), and probed for Hcp secretion. We found that
WT Ab17978 expressing VgrGi secreted similar levels of Hcp compared to the vector
control (Fig. 4a and Fig. S2). This result suggested that VgrGi is unable to inhibit the
T6SS of a noncognate host. Nonetheless, it is noteworthy that unlike AbCAN2, which
encodes one canonical VgrG, VgrG2, Ab17978 encodes four VgrG homologs, each
sufﬁcient for assembling a functional T6SS (46). We reasoned that it was possible that
VgrGi was unable to inhibit the T6SS of Ab17978 due to functional redundancy
between the four VgrGs. Therefore, we then expressed VgrGi in mutant strains of
Ab17978 lacking one to three VgrGs. We found that VgrGi expression in
Ab17978⌬vgrG1 resulted in a considerable reduction of Hcp detected in culture supernatants (Fig. 4b). Remarkably, VgrGi completely abolished Hcp secretion in Ab17978

FIG 4 VgrGi inhibits the T6SS of VgrG mutant strains of Ab17978. Western blot analyses of ODnormalized whole-cell (WC) and supernatant (Sup) fractions of wild-type (WT) Ab17978 (a) or the mutant
strains ⌬vgrG1 (b), ⌬vgrG1,2 (c) or ⌬vgrG1,2,3 (d) were performed, probing for Hcp expression and
secretion. RNAP is included as a lysis and loading control. The Western blots shown are representative
of three independent experiments.
January/February 2020 Volume 11 Issue 1 e02761-19
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FIG 5 Arginine residue in DUF2345 domain of VgrGi is necessary for T6SS inhibition. (a) Schematic of the predicted structure
of VgrGi based on the crystal structure of the P. aeruginosa VgrG1 (PDB 4MTK). Different domains are represented in different
colors: gp27 (blue), OB-fold (red), and gp5 (green). The coiled-coil (cc), DUF2345 (dark gray rectangle), and transthyretin (TT;
light gray rectangle) domains could not be modeled. Yellow and white rectangles represent areas for which no domain is
predicted. The conceptualization of this ﬁgure borrowed heavily from Renault et al. (52). (b) Amino acid alignment of VgrGi
with other class 1 VgrGs, according to the nomenclature of Fitzsimons et al. (58). Identical residues are highlighted in blue. In
panels a and b, the asterisk highlights the L749R mutation present in VgrGi relative to other VgrGs of the same phylogenetic
group. (c and d) Western blots probing for Hcp expression and secretion. OD-normalized whole-cell (WC) and supernatant
(Sup) fractions of AbCAN2⌬vgrGi (c) or ⌬vgrGi,2 (d) expressing VgrGi, VgrGi R749L, or a vector control (pWH) are shown. RNAP
was included as a lysis and loading control. The Western blots shown are representative of three independent experiments.

⌬vgrG1,2 and ⌬vgrG1,2,3 (Fig. 4c and d), indicating that the inhibitory capability of
VgrGi extends beyond AbCAN2.
Taken together, our results show that VgrGi can inhibit the T6SS of its native strain,
as well as that of Ab17978 mutant strains with limited VgrGs. Given that AbCAN2 and
Ab17978 possess a different arsenal of effectors, these ﬁndings provide further evidence that VgrGi-mediated T6SS inhibition is independent of the effectors expressed.
VgrGi-mediated T6SS inhibition is due to a leucine-to-arginine mutation. VgrGi
is, to the best of our knowledge, the ﬁrst VgrG homolog with an ability to inhibit the
T6SS. Thus, we sought to identify unique characteristics that differentiate VgrGi from
other VgrGs. However, protein sequence and structural prediction analyses revealed
that VgrGi contains domains similar to those found in canonical VgrGs of diverse
bacteria, such as VgrG1 of P. aeruginosa PAO1 (VgrG1Pa) and VgrG1 of EAEC 17-2
(VgrG1Ec) (52, 54, 57). (Despite their similar names, VgrG1Pa and VgrG1Ec are two distinct
proteins.) VgrGi contains two domains at its N terminus that closely resemble bacteriophage T4 tail spike proteins gp27 (residues 1 to 426) and gp5 (residues 537 to 666)
(Fig. 5a). These domains are linked by an oligosaccharide-binding (OB)-fold domain
(residues 427 to 536). The C terminus of VgrGi is composed of a DUF2345 domain
(residues 688 to 834), followed by a TT-like domain (residues 860 to 907) and a region
of ⬃130 residues with no predicted functional domains. Finally, the N- and C-terminal
segments of VgrGi are linked by a predicted coiled-coil region (residues 667 to 687)
(Fig. 5a).
Given that we identiﬁed no differences in the predicted functional domains of
canonical VgrGs and those of VgrGi, we reasoned that VgrGi may possess critical
differences in its primary sequence that are responsible for its inhibitory ability. VgrGs
encoded by A. baumannii strains were recently grouped into six distinct phylogenetic
January/February 2020 Volume 11 Issue 1 e02761-19
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FIG 6 Leucine-to-arginine substitution converts canonical VgrG1 to an inhibitory VgrG. Western blot
analysis of Ab17978⌬vgrG1 expressing pWH (empty vector), VgrG1, or VgrG1 L758R probing for Hcp
expression and secretion was performed. To facilitate the visualization of Hcp in the supernatant fractions
of strains expressing pWH and L758R, twice the amount of supernatant from these strains (as determined
by the OD) was loaded relative to Ab17978⌬vgrG1 expressing VgrG1. RNAP was included as a lysis and
loading control. The Western blot shown is representative of three independent experiments.

groups (58). Based on the amino acid identity (⬎95%), we determined that VgrGi
belongs to class 1 VgrGs. Interestingly, despite such remarkable levels of sequence
conservation, we found that VgrGi contains a leucine-to-arginine substitution in position 749 compared to all other class 1 VgrGs (Fig. 5b). We hypothesized that the
leucine-to-arginine mutation was responsible for the unprecedented ability of VgrGi to
inhibit the T6SS of A. baumannii. To test our hypothesis, we expressed plasmid-borne
6⫻His-tagged VgrGi or a VgrGi revertant mutant containing an arginine-to-leucine
mutation (hereafter referred to simply as R749L) in AbCAN2⌬vgrGi and probed for Hcp
secretion. As expected, we detected Hcp in the supernatant of the vector control but
not in the vgrGi⫹ strain (Fig. 5c). Remarkably, ⌬vgrGi expressing R749L (vgrGiR749L⫹)
retained T6SS activity (Fig. 5c and Fig. S3a), indicating that the mutation R749L
abrogated the inhibitory capability of VgrGi. In fact, vgrGiR749L⫹ showed higher levels
of Hcp secretion compared to the vector control (Fig. 5c), suggesting that R749L likely
participates in T6SS assembly. To test this, we expressed plasmid-borne 6⫻His-tagged
VgrGi or R749L in AbCAN2⌬vgrGi,2. This strain lacks T6SS activity (Fig. 3) but encodes
all other genes necessary to assemble a functional T6SS. Thus, we hypothesized that if
R749L participates in T6SS assembly, heterologous expression of this protein in ⌬vgrGi,2
would result in T6SS activity. Indeed, ⌬vgrGi,2 expressing R749L but not VgrGi or the
empty vector secretes Hcp (Fig. 5d and Fig. S3b), indicating that the mutation R749L
converts VgrGi to a canonical VgrG essential to T6SS assembly.
Altogether, our results indicate that VgrGi lacks any functional domains that differentiate it from canonical VgrGs. Instead, its inhibitory capability is due to a single amino
acid mutation.
Polar or charged residues within the SLFAAQ motif disrupt VgrG function. Our
previous result suggests that a leucine residue in position 749 plays an important role
in canonical VgrG function. A protein alignment analysis revealed that despite considerable levels of divergence among VgrGs of diverse A. baumannii strains, most VgrGs
possess a conserved SLFAAQ motif (Fig. S4). The conservation of this motif further
points to the leucine residue as important for VgrG function. Thus, we hypothesized
that substitution of the conserved leucine for arginine would convert a canonical VgrG
to an inhibitory VgrG. VgrG1 of Ab17978 (ACX60_17665) possesses a leucine residue
within its SLFAAQ motif, L758 (Fig. S4), and is important for T6SS function (46). To test
our hypothesis, we generated plasmid-borne 6⫻His-tagged VgrG1 or VgrG1 bearing a
L758R mutation, expressed them in Ab17978⌬vgrG1 (vgrG1⫹ and vgrG1L758R⫹, respectively) (Fig. S5), and determined the resulting levels of Hcp secretion. In contrast with
the vgrG1⫹ strain, which had increased levels of Hcp secretion compared to the vector
control, vgrG1L758R⫹, demonstrated a marginal level of Hcp secretion (Fig. 6). This result
indicates that substitution of a conserved leucine residue for arginine confers on VgrG1
the ability to repress the T6SS of Ab17978.
Next, we tested whether VgrGi-mediated T6SS inhibition depends on a speciﬁc
property of arginine or whether other amino acids yield similar phenotypes. To this end,
January/February 2020 Volume 11 Issue 1 e02761-19
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FIG 7 Polar and charged residues in position 749 result in T6SS inhibition by VgrGi. Western blot probing
for Hcp expression and secretion was performed. OD-normalized whole-cell (WC) and supernatant (Sup)
fractions of AbCAN2⌬vgrGi expressing the indicated VgrGi point mutants were assessed. RNAP was
included as a lysis and loading control. The Western blot shown is representative of three independent
experiments.

we generated pWH1266 vector constructs containing the following point mutants of
VgrGi: R749K, R749D, R749N, and R749F. Then, we expressed these VgrGi variants in
AbCAN2⌬vgrGi (Fig. S6) and determined whether expression of these constructs results
in T6SS inhibition. We found that VgrGi variants containing polar or charged residues
(i.e., R749K, R749D, and R749N) inhibit Hcp secretion (Fig. 7). In contrast, VgrGi variants
containing nonpolar residues (i.e., R749L and R749F) do not inhibit Hcp secretion
(Fig. 7). Similar results were obtained when these constructs were expressed in
Ab17978⌬vgrG1,2 (Fig. S7). Collectively, our results indicate that polar or charged
residues in the second position of the SLFAAQ motif disrupt the canonical function of
VgrGs in T6SS assembly.
The C terminus of VgrG is essential to T6SS function in A. baumannii. The
SLFAAQ motif lies within the C-terminal DUF2345 domain of VgrGi. Although present
in VgrGs of diverse Gram-negative bacteria, the role of the DUF2345 domain in T6SS
assembly remains poorly understood. Recent work in E. coli showed that the gp27
domain of VgrG1Ec is sufﬁcient for T6SS activity, indicating that the DUF2345 and TT
domains are dispensable for T6SS assembly (52). Similarly, the C terminus of P.
aeruginosa VgrG5 is not required to support VgrG4b secretion (53). Nonetheless, our
results indicate that a point mutation within the C-terminal DUF2345 domain of A.
baumannii VgrGs is sufﬁcient to disrupt T6SS activity. Thus, we hypothesized that in A.
baumannii, the DUF2345 domain plays an essential role in the assembly of a functional
T6SS. To test our hypothesis, we expressed different truncations of R749L in
AbCAN2⌬vgrGi,2 and determined the resulting levels of Hcp secretion. As shown in
Figure 5d, ⌬vgrGi,2 lacks T6SS activity unless it expresses a functional VgrG (e.g.,
full-length R749L). The R749L constructs tested include the gp27 domain (gp27), a
C-terminal truncation ending with the gp5 domain (C-gp5), a C-terminal truncation
ending with the DUF2345 domain (C-DUFR749L), and mutants lacking either the
DUF2345 domain (ΔDUF) or the TT domain (ΔTTR749L) but possessing all other domains
(Fig. 8a and Fig. S8). We found that in contrast to full-length R749L, the expression of
none of the R749L truncations tested led to Hcp secretion (Fig. 8b). This result indicates
that the C terminus of R749L is essential to the role of VgrG in assembling a functional
T6SS.
DISCUSSION
The T6SS is a critical weapon for interbacterial warfare (12). Seminal studies have
provided general principles that are largely applicable to the T6SS of various bacterial
species. However, it is becoming increasingly clear that the T6SS is a diversiﬁed
machine, with important structural and functional differences depending on the bacterial host (31, 59, 60). Here, we identiﬁed a VgrG homolog with an unprecedented
ability to inhibit the T6SS of the clinical isolate AbCAN2. Our efforts to characterize the
mechanism underlying VgrGi-mediated T6SS inhibition led us to determine that the C
terminus of VgrG is essential for functional T6SS assembly in A. baumannii.
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FIG 8 The C terminus of VgrGiR749L is required for T6SS activity. (a) Schematic of the domains present
in VgrGiR749L, as well as the truncations made for the experiment in panel b. The amino acid boundaries
are indicated, and the color scheme is consistent with that of Fig. 5a. The asterisk indicates the position
of the R749L mutation. (b) Western blot analyses probing for Hcp expression (top) and secretion (bottom)
in AbCAN2⌬vgrGi,2 expressing the indicated VgrGiR749L truncations were carried out. RNAP was included
as a lysis and loading control. The Western blots shown are representative of three independent
experiments.

VgrG is one of the most versatile proteins of the T6SS. It is an essential structural
component of the baseplate and sharpens the Hcp tube to facilitate penetration into
adjacent cells and delivery of effectors (21, 22, 54). Despite its relevance, VgrG remains
largely understudied compared to other T6SS proteins, likely due to its inherent
insolubility (61). Only one full-length VgrG protein, VgrG1Pa, has been structurally
characterized (57). Notably, VgrG1Pa is much shorter compared to other VgrGs (643
amino acids [aa] versus 841 aa [VgrG1Ec] and 1,039 aa [VgrGi]). Thus, the functional
domains present in longer VgrGs remain largely uncharacterized.
One of the functional domains present in longer VgrGs is the DUF2345 domain. In
Escherichia coli, this domain has been shown to stabilize the interaction between the TT
domain of VgrG1 and effector Tle1, but it is dispensable for T6SS assembly and
dynamics (52, 54). Despite its seeming dispensability for T6SS assembly, this domain is
present in the VgrGs of a wide range of Gram-negative bacteria, including V. cholerae
(VCV52_2925), Klebsiella pneumoniae (BN49_3373), P. aeruginosa (PA0262), and Salmonella enterica (FJR63_23580). In fact, VgrGs were originally described as possessing a
COG4253 functional domain, which belongs to the DUF2345 superfamily (60). Our
results suggest that the DUF2345 domain may play a role in T6SS assembly in A.
baumannii. However, since C-DUFR749L is not sufﬁcient for T6SS assembly (Fig. 8), the
DUF2345 domain may require additional elements present at the C terminus of VgrG
for proper function. Moreover, a recent bioinformatic analysis of 73 VgrGs across 22 A.
baumannii strains, as well as the soil bacterium A. baylyi ADP1, showed that all VgrGs
contain a DUF2345 domain (58). The high levels of conservation suggest that the
January/February 2020 Volume 11 Issue 1 e02761-19
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DUF2345 domain may play a particularly important role in the T6SS of Acinetobacter
species.
It is noteworthy that our results are not in conﬂict with previous results indicating
that the C terminus of VgrG is dispensable for T6SS function (52, 53). Instead, we
propose that over evolutionary time, bacteria developed changes to their T6SS architecture, leading to specialized systems. Indeed, it was recently reported that TssA
homologs carry out three diverse functions depending on their C-terminal domain (62).
Moreover, homologs of membrane complex protein TssM possess a Walker A motif;
however, no general role for this motif has been described. In Agrobacterium tumefaciens, for instance, TssM exhibits ATP binding and hydrolysis, as well as ATP-bindingdependent conformational changes, all of which are implicated in T6SS function (63,
64). In contrast, the Walker A motif of the Edwardsiella tarda TssM, is dispensable for
T6SS activity (65). Thus, it seems likely that bacteria have co-opted conserved structural
proteins to better suit their needs.
Future work will characterize the mechanism by which VgrGi inhibits the T6SS, since
it may provide insight into the role of the C terminus of A. baumannii VgrGs. Our ﬁnding
that VgrGi inhibits the T6SS of Ab17978 only when endogenous VgrGs are limited
suggests that VgrGi acts at the posttranslational level. We propose that VgrGi likely
inhibits the T6SS by preventing its assembly. VgrGs can form heterotrimeric assemblies
(21, 53, 66, 67). Thus, it is possible that VgrGi binds canonical VgrGs and prevents
essential protein-protein interactions with other structural components of the T6SS.
PAAR proteins, for instance, bind VgrG proteins at their C termini (68). In A. baylyi, PAAR
proteins are essential for effective T6SS ﬁring (68). Thus, VgrG trimers containing VgrGi
may be unable to bind PAAR proteins, which would be expected to disrupt T6SS
assembly. Moreover, it is possible that VgrGi possesses conformational changes that
abrogate critical baseplate-membrane complex interactions. Alternatively, it is possible
that VgrGi acts post-T6SS assembly. The T6SS is expected to undergo two large
conformational changes to enable deployment of the spiked tube. First, conformational
changes in the baseplate are proposed to trigger sheath contraction (22, 69, 70).
Second, the membrane complex is expected to undergo large conformational changes
to enable the passage of the spiked tube (19, 71). It is possible that a leucine-to-arginine
mutation causes aberrant interactions between VgrG and components of the membrane complex or baseplate, which prevent the necessary conformational changes for
T6SS ﬁring. In this instance, VgrGi may prove to be an invaluable tool to lock the
dynamic T6SS in a static conformation and facilitate the structural characterization of
the Acinetobacter T6SS.
Finally, it is noteworthy that we found an inactivating mutation of the T6SS in a
clinical isolate. Although we cannot say with certainty whether this mutation was
acquired during culturing or in the human host, it is tempting to speculate that there
may be a selective pressure against the T6SS of medically relevant strains. As previously
mentioned, the T6SS is an energetically expensive machine. Thus, there may be beneﬁts
to inactivating this machine, for example, to conserve energy. Moreover, T6SS structural
components have been shown to be immunogenic (13, 72). It is possible that T6SSinactive strains are selected for in the human host, since they are more likely to bypass
detection by the immune system. In fact, most of the characterized virulence factors of
A. baumannii involve evading immune detection or overcoming nutritional immunity
(38). Thus, eliminating the T6SS may represent yet another strategy to bypass immune
detection. Nonetheless, the T6SS confers a competitive advantage to nonpathogenic
bacteria living in polymicrobial communities. Thus, it is likely that the environment
exerts selective pressure in favor of a silenced T6SS in clinical A. baumannii strains and
a constitutively active T6SS in nonpathogenic strains, as was previously proposed for V.
cholerae (29). Indeed, clinical isolates of A. baumannii often have a nonfunctional T6SS
due to genetic disruptions or absence of T6SS genes (44, 73–75). Our work indicates
that point mutations at critical residues of T6SS structural proteins could constitute an
underappreciated mechanism by which the T6SS is genetically disrupted.
Collectively, we have demonstrated that unlike in other bacteria, the C terminus of
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VgrG is essential to functional T6SS assembly in A. baumannii. The speciﬁc roles of the
DUF2345 and other C-terminal domains of VgrGs warrant further investigation.
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Bacterial strains and growth conditions. All strains and plasmids used in this study are listed in
Table S2. Strains were grown in Luria-Bertani (LB) broth at 37°C with shaking. Antibiotics were added to
the media when appropriate (see below).
Transposon mutagenesis and screen T6SS-active mutants. Our method for transposon mutagenesis has been described previously (41). Plasmid pSAM::OmpAp⫹Tn903 was introduced to AbCAN2 from
E. coli BW19851 by biparental mating. Brieﬂy, overnight cultures were pelleted, washed three times with
fresh LB medium, and resuspended at an optical density at 600 nm (OD600) of 1.0. The cultures were then
mixed at a 1:1 ratio and spotted onto a dry LB agar plate. After a 5-h incubation at 37°C, the spot was
resuspended in 1 ml of LB broth, and 10-fold dilutions were plated on LB agar containing kanamycin
(20 g/ml) plus chloramphenicol (12.5 g/ml), followed by incubation overnight at 37°C. The transposon
mutants obtained were subsequently subjected to a colony blot (51) to identify mutants with an active
T6SS. Brieﬂy, colonies were transferred to a nitrocellulose membrane and allowed to dry at room
temperature for 30 min. The dried membrane is washed twice with Tris-buffered saline–Tween and
treated as a normal Western blot, probing for Hcp and RNAP (see below). Candidates were then isolated
and veriﬁed using a standard Hcp secretion assay (see below).
Identiﬁcation of transposon insertion sites was carried out using a method adapted from Goodman
et al. (76). Transposon mutant gDNA was digested with MmeI and separated on a 0.7% agarose gel by
electrophoresis. Fragments ⬃500 and ⬃1,600 bp in length were extracted and appended with doublestranded oligonucleotide sequencing adapters by ligation. Finally, the transposon plus two 16-bp
genomic sequences ﬂanking the transposon was ampliﬁed by PCR and sequenced. The insertion site was
veriﬁed by amplifying a genomic fragment of the putative insertion site by PCR and sequencing that
fragment as well.
Hcp secretion assay and Western blot analysis. Overnight cultures were back-diluted in fresh LB
medium to an OD600 of 0.025 and grown at 37°C with shaking until they reached an OD600 of 0.35 to 0.5
(AbCAN2) or 0.4 to 0.7 (Ab17978). The cells were then pelleted by centrifugation. The cells were
resuspended in Laemmli buffer to a ﬁnal OD600 of 10, while the supernatant fraction was centrifuged
once again (as above) to pellet residual cells. Supernatant proteins were subsequently precipitated with
trichloroacetic acid, as previously described (39). Optical desity-normalized volumes of whole cells or
supernatants were loaded onto 15% (for Hcp) or 8% (for VgrGs) SDS-PAGE gels for separation, transferred
to a nitrocellulose membrane, and probed with polyclonal rabbit anti-Hcp (1:1,000) (39), polyclonal rabbit
anti-6⫻His (1:2,000; Invitrogen, Waltham, MA) or monoclonal mouse anti-RNA polymerase (1:2,600;
BioLegend, San Diego, CA). Western blots were then probed with IRDye-conjugated anti-mouse and
anti-rabbit secondary antibodies (both at 1:15,000; LI-COR Biosciences, Lincoln, NE) and visualized with
an Odyssey CLx imaging system (LI-COR Biosciences).
Generation of mutants and pWH constructs. The primers used in this study are listed in Table S2.
Marked mutant strains were generated by substitution of the gene of interest by a kanamycin resistance
marker, as described previously (77). Selection was carried out using kanamycin (30 g/ml). To generate
clean mutants, electrocompetent marked mutants were transformed with pAT03 to remove the FRTﬂanked kanamycin resistance cassette. Transformants were plated on LB agar containing 2 mM IPTG
(isopropyl-␤-D-thiogalactopyranoside) plus hygromycin (600 g/ml). Mutant strains were veriﬁed by PCR
and sequencing.
Constructs pWH-vgrGi-6⫻His and pWH-vgrG1-6⫻His were generated by restriction cloning using the
EcoRI and PstI sites. These plasmids were then used as templates to make point mutants of VgrGi and
VgrG1, respectively. Speciﬁcally, point mutants were generated using the QuikChange II site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s instructions.
Constructs of VgrGi truncations ΔDUF and ΔTTR749L were generated by inverse PCR of pWH-vgrGi-6⫻His,
followed by blunt ligation. All other VgrGi truncation constructs were generated by restriction cloning,
as described above. Selection was carried out using tetracycline (15 g/ml for AbCAN2 and 10 g/ml for
Ab17978). All constructs were veriﬁed by PCR and sequencing.
Bacterial killing assay. Overnight cultures were washed three times with fresh LB and normalized
to an OD600 of 1. Predator and prey strains were mixed at a 10:1 ratio, respectively, and spotted on dry
LB agar. After a 3.5-h incubation at 37°C, spots were resuspended in LB medium, and serial dilutions were
spotted on LB agar with the appropriate antibiotic (kanamycin 50 g/ml for E. coli MG1655R/pBAV-gfp
and tetracycline 15 g/ml for E. coli HB101/pWH1266). The CFU of surviving prey cells were enumerated
after overnight incubation at 37°C.
VgrGi structural model and alignments. VgrGi C-gp5 (residues 1 to 666) was submitted to the
iterative threading assembly reﬁnement (I-TASSER) server (78), using the crystal structure of P. aeruginosa
PAO1 VgrG1 (PDB 4MTK) as a template without alignment. The trimer assembly was constructed by
aligning the VgrGi model to each VgrG1Pa monomer in Biological Assembly 1 (PDB 4MTK), using the
PyMOL Molecular Graphics System (v1.2r3pre; Schrödinger, LLC).
Domain designations were made according to Interpro (79) and HHPred (80) servers. The predictions
for the coiled-coil domain and the DUF2345 domain overlap in residues 668 to 697; however, for the
construction of the VgrGi truncations, preference was given to the DUF2345 domain. Sequence alignments were done using Clustal Omega (81).
Data availability. The genome of AbCAN2 (formerly named Ab1225) was deposited to GenBank
under accession number CP045428.
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